A case report and literature review on anakinra in the treatment of refractory adult onset Still’s disease

YAN Yumin; LIU Jie; ZHANG Xia; ZHONG Xue

doi:10.6039/j.issn.1001-0408.2025.19.15

您当前的位置：

首页 >

文章列表页 >

A case report and literature review on anakinra in the treatment of refractory adult onset Still’s disease

更新时间：2025-10-11

- A case report and literature review on anakinra in the treatment of refractory adult onset Still’s disease
- ZHONGGUO YAOFANG Vol. 36, Issue 19, Pages: 2442-2447(2025)
- 作者机构：
  
  1.北京大学人民医院药学部，北京　100044
  2.中山市人民医院临床药学科，广东中山　528400
  3.济宁医学院附属医院临床药学科，山东济宁　272000
  4.北京大学人民医院风湿免疫科，北京　100044
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.19.15
  CLC： R593.2;R969.3
- Received：09 June 2025，
  
  Revised：2025-07-11，
  
  Accepted：08 September 2025，
  
  Published：15 October 2025
- 稿件说明：
移动端阅览
严钰敏,刘洁,张霞,等.阿那白滞素治疗1例难治性成人斯蒂尔病及文献复习[J].中国药房,2025,36(19):2442-2447.

YAN Yumin,LIU Jie,ZHANG Xia,et al.A case report and literature review on anakinra in the treatment of refractory adult onset Still’s disease[J].ZHONGGUO YAOFANG,2025,36(19):2442-2447.
严钰敏,刘洁,张霞,等.阿那白滞素治疗1例难治性成人斯蒂尔病及文献复习[J].中国药房,2025,36(19):2442-2447. DOI： 10.6039/j.issn.1001-0408.2025.19.15.

YAN Yumin,LIU Jie,ZHANG Xia,et al.A case report and literature review on anakinra in the treatment of refractory adult onset Still’s disease[J].ZHONGGUO YAOFANG,2025,36(19):2442-2447. DOI： 10.6039/j.issn.1001-0408.2025.19.15.

摘要

目的

探讨白细胞介素1（IL-1）受体拮抗剂阿那白滞素治疗难治性成人斯蒂尔病（AOSD）的疗效与安全性，为该药治疗AOSD提供更多的真实世界证据和实践经验。

方法

回顾性分析1例AOSD合并皮肌炎患者应用阿那白滞素的诊疗过程；在中国知网、PubMed、Medline等中英文数据库中系统检索阿那白滞素治疗AOSD的相关文献，对其疗效与安全性进行文献复习。

结果

本例患者经多种传统药物治疗效果不佳，考虑为AOSD合并皮肌炎。入院改用阿那白滞素联合糖皮质激素治疗数天后，患者临床症状及炎症指标显著改善，未发生严重不良反应。药师为其设计专门的药学监护路径并在出院后定期随访。出院后患者规律用药，病情维持缓解；期间出现过一次注射部位红肿并自行缓解，无其他明显不适。文献复习显示，阿那白滞素可使AOSD患者具有较高的反应率和缓解率，可显著减少糖皮质激素用量；不良事件以注射部位反应为主，总体感染风险较低，安全性良好；但疗程差异较大，目前尚无统一方案。

结论

阿那白滞素是治疗AOSD的高效且安全的生物制剂，可快速诱导并维持病情缓解。对于AOSD患者，临床可考虑选用IL-1拮抗剂以减少糖皮质激素依赖，同时应加强长期用药监测。

Abstract

OBJECTIVE

To investigate the efficacy and safety of the interleukin-1 （IL-1） receptor antagonist anakinra in the treatment of refractory adult onset Still’s disease （AOSD）， and provide more real-world evidence and practical experience for the treatment of AOSD with this drug.

METHODS

A retrospective analysis was conducted on the diagnosis and treatment process of a patient with AOSD complicated with dermatomyositis who received anakinra； systematically searched for relevant literature on the treatment of AOSD with anakinra in Chinese and English databases such as CNKI， PubMed， Medline， etc.， and conduct literature review on its efficacy and safety.

RESULTS

The patient in this case had poor treatment with multiple traditional drugs and was considered to have AOSD combined with dermatomyositis. After being admitted to the hospital and treated with a combination therapy of anakinra and glucocorticoids for several days， the patient’s clinical symptoms and inflammatory indicators significantly improved， and no serious adverse drug reactions occurred. Pharmacists designed specialized pharmaceutical monitoring pathways and conduct regular follow-up after discharge. After discharge， the patient took medication regularly， and the condition was maintained and relieved； during this period， there was redness and swelling at the injection site which resolved on its own without any other obvious discomfort. Literature review showed that anakinra could increase the response rate and remission rate of AOSD patients， and significantly reduce the dosage of glucocorticoids； adverse events were mainly injection site reactions， with a low overall risk of infection and good safety； however， there was a significant difference in the treatment course， and there was currently no unified plan.

CONCLUSIONS

Anakinra is an efficient and safe biological agent for treating AOSD， which can rapidly induce and maintain disease remission. For AOSD patients， clinical consideration may be given to using IL-1 antagonists to reduce glucocorticoid dependence， while strengthening long-term medication monitoring.

关键词

Keywords

references

EFTHIMIOU P ， KONTZIAS A ， HUR P ， et al . Adult-onset Still’s disease in focus：clinical manifestations，diagnosis，treatment，and unmet needs in the era of targeted therapies [J ] . Semin Arthritis Rheum ， 2021 ， 51 （ 4 ）： 858 - 874 .

LI R ， LIU X L ， CHEN G L ， et al . Clinical phenotypes and prognostic factors of adult-onset Still’s disease：data from a large inpatient cohort [J ] . Arthritis Res Ther ， 2021 ， 23 （ 1 ）： 300 .

BINDOLI S ， BAGGIO C ， DORIA A ， et al . Adult-onset Still’s disease （AOSD）：advances in understanding pathophysiology，genetics and emerging treatment options [J ] . Drugs ， 2024 ， 84 （ 3 ）： 257 - 274 .

FAUTREL B ， MITROVIC S ， DE MATTEIS A ， et al . EULAR/PReS recommendations for the diagnosis and management of Still’s disease，comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease [J ] . Ann Rheum Dis ， 2024 ， 83 （ 12 ）： 1614 - 1627 .

YAMAMOTO T . Cutaneous manifestations associated with adult-onset Still’s disease：important diagnostic values [J ] . Rheumatol Int ， 2012 ， 32 （ 8 ）： 2233 - 2237 .

FERNÁNDEZ CAMPORRO Á ， RODRIGUEZ DIAZ E ， BETETA GORRITI V ， et al . Still disease with persistent atypical dermatomyositis-like skin eruption：two cases associated with macrophage activation syndrome [J ] . Clin Exp Dermatol ， 2022 ， 47 （ 11 ）： 1991 - 1994 .

DEWANE M E ， WALDMAN R ， LU J . Dermatomyositis：clinical features and pathogenesis [J ] . J Am Acad Dermatol ， 2020 ， 82 （ 2 ）： 267 - 281 .

FITZGERALD A A ， LECLERCQ S A ， YAN A ， et al . Rapid responses to anakinra in patients with refractory adult-onset Still’s disease [J ] . Arthritis Rheum ， 2005 ， 52 （ 6 ）： 1794 - 1803 .

KALLIOLIAS G D ， GEORGIOU P E ， ANTONOPOULOS I A ， et al . Anakinra treatment in patients with adult-onset Still’s disease is fast，effective，safe and steroid sparing：experience from an uncontrolled trial [J ] . Ann Rheum Dis ， 2007 ， 66 （ 6 ）： 842 - 843 .

KÖTTER I ， WACKER A ， KOCH S ， et al . Anakinra in patients with treatment-resistant adult-onset Still’s disease：four case reports with serial cytokine measurements and a review of the literature [J ] . Semin Arthritis Rheum ， 2007 ， 37 （ 3 ）： 189 - 197 .

LEQUERRÉ T ， QUARTIER P ， ROSELLINI D ， et al . Interleukin-1 receptor antagonist （anakinra） treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease：preliminary experience in France [J ] . Ann Rheum Dis ， 2008 ， 67 （ 3 ）： 302 - 308 .

NAUMANN L ， FEIST E ， NATUSCH A ， et al . IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease [J ] . Ann Rheum Dis ， 2010 ， 69 （ 2 ）： 466 - 467 .

LASKARI K ， TZIOUFAS A G ， MOUTSOPOULOS H M . Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease：a case-series study [J ] . Arthritis Res Ther ， 2011 ， 13 （ 3 ）： R91 .

RIERA E ， OLIVÉ A ， NARVÁEZ J ， et al . Adult onset Still’s disease：review of 41 cases [J ] . Clin Exp Rheumatol ， 2011 ， 29 （ 2 ）： 331 - 336 .

NORDSTRÖM D ， KNIGHT A ， LUUKKAINEN R ， et al . Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease：an open，randomized，multicenter study [J ] . J Rheumatol ， 2012 ， 39 （ 10 ）： 2008 - 2011 .

GIAMPIETRO C ， RIDENE M ， LEQUERRE T ， et al . Anakinra in adult-onset Still’s disease：long-term treatment in patients resistant to conventional therapy [J ] . Arthritis Care Res （Hoboken）， 2013 ， 65 （ 5 ）： 822 - 826 .

ILIOU C ， PAPAGORAS C ， TSIFETAKI N ， et al . Adult-onset Still’s disease：clinical，serological and therapeutic considerations [J ] . Clin Exp Rheumatol ， 2013 ， 31 （ 1 ）： 47 - 52 .

HONG D S ， YANG Z H ， HAN S Y ， et al . Interleukin 1 inhibition with anakinra in adult-onset Still disease：a meta-analysis of its efficacy and safety [J ] . Drug Des Devel Ther ， 2014 ， 8 ： 2345 - 2357 .

MARIA A T J ， LE QUELLEC A ， JORGENSEN C ， et al . Adult onset Still’s disease （AOSD） in the era of biologic therapies：dichotomous view for cytokine and clinical expressions [J ] . Autoimmun Rev ， 2014 ， 13 （ 11 ）： 1149 - 1159 .

GERFAUD-VALENTIN M ， MAUCORT-BOULCH D ， HOT A ， et al . Adult-onset Still disease：manifestations，treatment，outcome，and prognostic factors in 57 patients [J ] . Medicine （Baltimore）， 2014 ， 93 （ 2 ）： 91 - 99 .

CAVALLI G ， FRANCHINI S ， AIELLO P ， et al . Efficacy and safety of biological agents in adult-onset Still’s disease [J ] . Scand J Rheumatol ， 2015 ， 44 （ 4 ）： 309 - 314 .

ORTIZ-SANJUÁN F ， BLANCO R ， RIANCHO-ZARRABEITIA L ， et al . Efficacy of anakinra in refractory adult-onset Still’s disease：multicenter study of 41 patients and literature review [J ] . Medicine （Baltimore）， 2015 ， 94 （ 39 ）： e1554 .

ROSSI-SEMERANO L ， FAUTREL B ， WENDLING D ， et al . Tolerance and efficacy of off-label anti-interleukin-1 treatments in France：a nationwide survey [J ] . Orphanet J Rare Dis ， 2015 ， 10 ： 19 .

LENERT A ， YAO Q P . Macrophage activation syndrome complicating adult onset Still’s disease：a single center case series and comparison with literature [J ] . Semin Arthritis Rheum ， 2016 ， 45 （ 6 ）： 711 - 716 .

VITALE A ， INSALACO A ， SFRISO P ， et al . A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists：a nationwide multi-center retrospective observational study [J ] . Front Pharmacol ， 2016 ， 7 ： 380 .

SFRISO P ， PRIORI R ， VALESINI G ， et al . Adult-onset Still’s disease：an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients [J ] . Clin Rheumatol ， 2016 ， 35 （ 7 ）： 1683 - 1689 .

COLAFRANCESCO S ， PRIORI R ， VALESINI G ， et al . Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still’s disease：a multicentre retrospective observational study [J ] . Front Pharmacol ， 2017 ， 8 ： 369 .

NÉEL A ， WAHBI A ， TESSOULIN B ， et al . Diagnostic and management of life-threatening adult-onset Still disease：a French nationwide multicenter study and systematic literature review [J ] . Crit Care ， 2018 ， 22 （ 1 ）： 88 .

VERCRUYSSE F ， BARNETCHE T ， LAZARO E ， et al . Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy [J ] . Arthritis Res Ther ， 2019 ， 21 （ 1 ）： 53 .

VASTERT S J ， JAMILLOUX Y ， QUARTIER P ， et al . Anakinra in children and adults with Still’s disease [J ] . Rheumatology （Oxford）， 2019 ， 58 （ Suppl. 6 ）： 9 - 22 .

RUSCITTI P ， URSINI F ， SOTA J ， et al . The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still’s disease. A systematic review and meta-analysis of observational studies [J ] . Ther Adv Musculoskelet Dis ， 2020 ， 12 ： 1759720 X 20933133 .

MONTEAGUDO L A ， BOOTHBY A ， GERTNER E . Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome [J ] . ACR Open Rheumatol ， 2020 ， 2 （ 5 ）： 276 - 282 .

ÇOLAK S ， TEKGÖZ E ， MAMMADOV M ， et al . Biological treatment in resistant adult-onset Still’s disease：a single-center，retrospective cohort study [J ] . Arch Rheumatol ， 2021 ， 37 （ 1 ）： 11 - 18 .

BINDOLI S ， GALOZZI P ， DORIA A ， et al . Intravenous anakinra to curb cytokine storm in adult-onset Still’s disease and in macrophage activation syndrome：a case series [J ] . Joint Bone Spine ， 2023 ， 90 （ 2 ）： 105524 .

BITIK B ， ŞENTURK M ， KIBAROGLU S ， et al . Intravenous anakinra for treating macrophage activation syndrome in adult-onset Still’s disease [J ] . Eur J Case Rep Intern Med ， 2024 ， 11 （ 11 ）： 004788 .

KERNDER A ， FILLA T ， FRIEDRICH R ， et al . First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still’s disease：a multicentre，retrospective，propensity weighted cohort study [J ] . Lancet Rheumatol ， 2025 ， 7 （ 6 ）： e415 - e423 .

KILIC B ， PARLAR K ， KARUP S ， et al . Anakinra in the management of adult-onset Still’s disease：a single-center experience [J ] . Intern Emerg Med ， 2025 ， 20 （ 1 ）： 131 - 138 .

VITALE A ， CAVALLI G ， RUSCITTI P ， et al . Comparison of early vs. delayed anakinra treatment in patients with adult onset Still’s disease and effect on clinical and laboratory outcomes [J ] . Front Med （Lausanne）， 2020 ， 7 ： 42 .

MEHTA P ， CRON R Q ， HARTWELL J ， et al . Silencing the cytokine storm：the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome [J ] . Lancet Rheumatol ， 2020 ， 2 （ 6 ）： e358 - e367 .

COLAFRANCESCO S ， MANARA M ， BORTOLUZZI A ， et al . Management of adult-onset Still’s disease with interleukin-1 inhibitors：evidence- and consensus-based statements by a panel of Italian experts [J ] . Arthritis Res Ther ， 2019 ， 21 （ 1 ）： 275 .

BINDOLI S ， DE MATTEIS A ， MITROVIC S ， et al . Efficacy and safety of therapies for Still’s disease and macrophage activation syndrome （MAS）：a systematic review informing the EULAR/PReS guidelines for the management of Still’s disease [J ] . Ann Rheum Dis ， 2024 ， 83 （ 12 ）： 1731 - 1747 .

SETTAS L D ， TSIMIRIKAS G ， VOSVOTEKAS G ， et al . Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists （anakinra） [J ] . J Clin Rheumatol ， 2007 ， 13 （ 4 ）： 219 - 220 .

MIGKOS M P ， SOMARAKIS G A ， MARKATSELI T E ， et al . Tuberculous pyomyositis in a rheumatoid arthritis patient treated with anakinra [J ] . Clin Exp Rheumatol ， 2015 ， 33 （ 5 ）： 734 - 736 .

国家传染病医学中心，复旦大学附属华山医院 . 免疫抑制剂与结核潜伏感染激活的临床专家共识： 2025版 [J ] . 中华传染病杂志， 2024 ， 42 （ 12 ）： 715 - 735 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰